May 20 |
Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise
|
May 20 |
Atara Biotherapeutics Submits Tabelecleucel (Tab-celĀ®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
|
May 11 |
Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
|
May 9 |
Atara Biotherapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $27.36M beats by $2.67M
|
May 9 |
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
|
May 9 |
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
|
Apr 5 |
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 28 |
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 28 |
Atara Biotherapeutics GAAP EPS of -$0.56 misses by $0.03, revenue of $4.25M misses by $10.01M
|
Mar 28 |
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
|